← Back to Search

Chatbot for Hereditary Cancer Risk Assessment

N/A

Recruiting

Led By Melissa K Frey, MD

Research Sponsored by Weill Medical College of Cornell University

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 2 years

Awards & highlights

No Placebo-Only Group

Summary

This trial will compare a mobile health platform that uses artificial intelligence and natural language processing (a 'chatbot') to usual care in order to determine if the chatbot system can improve rates of recommendation for genetic testing among patients at elevated risk of familial cancer syndrome in an all-Medicaid gynecology clinic.

Who is the study for?

This trial is for individuals aged 18 or older who are new patients at a gynecology clinic, speak and read English, and have access to text messaging on a phone. They should not have had genetic testing for hereditary cancer syndromes before.

What is being tested?

The study tests if a chatbot using artificial intelligence can increase recommendations for genetic testing in patients at high risk of familial cancer syndromes compared to the usual care in an all-Medicaid gynecology clinic.

What are the potential side effects?

Since this intervention involves communication via a chatbot, there are no direct physical side effects like those associated with medications or surgeries. However, participants may experience stress or anxiety related to discussing their genetic risks.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 2 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~2 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and 2 years for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Genetic screening method

Secondary study objectives

Genetic screening method

Facilitator of inequity in the utilization of genetic services

Genetic screening method

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups

Experimental Treatment

Active Control

Group I: ChatbotExperimental Treatment1 Intervention

Subjects will receive a text message initiating a chatbot conversation that relies on natural language processing to gather personal and family cancer. Subjects are identified by the chatbot as meeting National Comprehensive Cancer Network (NCCN) high-risk criteria. Next, subjects undergo pre-test genetic counseling via the chatbot and then clinicians are notified (via the chatbot portal) that the subject meets high-risk criteria. For subjects meeting high-risk criteria (based on the chatbot evaluation), the clinician will complete genetic counseling and recommend genetic testing during the visit. For subjects interested in genetic testing, the clinician will order genetic testing.

Group II: Usual CareActive Control1 Intervention

Personal and family cancer history will be collected by the clinician during the subject's visit. Clinicians will evaluate the patient's personal/family history according to National Comprehensive Cancer Network (NCCN) high-risk criteria. For subjects recognized by the clinician as meeting NCCN criteria, the clinician will complete genetic counseling and recommend genetic testing. For subjects interested in genetic testing, the clinician will order genetic testing.

Do I qualify?Apply below to find out